Can pro–B-type natriuretic peptide (ProBNP) be used to monitor heart failure management?

ProBNP for Tracking Heart Failure Management

While ProBNP (and NT-proBNP) levels are strongly recommended for diagnosis, risk stratification, and prognosis in heart failure, using serial measurements to guide treatment adjustments remains insufficient and is not currently recommended as a primary management strategy 1.

Current Guideline-Based Recommendations

The 2022 ACC/AHA/HFSA guidelines provide clear direction on when natriuretic peptides should be used 1:

Established Uses (Class 1 Recommendations):

• Diagnosis: BNP/NT-proBNP measurement is definitively useful for supporting or excluding HF diagnosis in patients with dyspnea
• Risk stratification: Recommended in chronic HF patients to assess prognosis
• Admission prognosis: Measurement at hospital admission establishes baseline risk

Limited Use for Serial Monitoring (No Class 1 Recommendation):

The guidelines explicitly state: "Although a reduction in BNP and NT-proBNP has been associated with better outcomes, the evidence for treatment guidance using serial BNP or NT-proBNP measurements remains insufficient" 1. This is the critical limitation for using ProBNP to "track" management.

What the Evidence Actually Shows

Prognostic Value vs. Treatment Guidance

The distinction is crucial:

• Predischarge measurements (Class 2a): Can inform trajectory and post-discharge prognosis, but this is about predicting outcomes, not directing therapy 1
• Serial measurements during hospitalization: Targeting specific thresholds or relative changes has not been shown to consistently improve outcomes 1

Why Serial Monitoring Falls Short

The 2017 AHA Scientific Statement reinforces this limitation 2. While natriuretic peptides successfully identify higher-risk patients in clinical trials (like PARADIGM-HF and EMPHASIS-HF), these were used for enrollment criteria, not as treatment targets.

Research data shows that while patients whose BNP/NT-proBNP decreased with treatment had better outcomes, this association does not translate into improved outcomes when actively targeting biomarker levels 3. The GUIDE-IT and PRIMA trials demonstrated no benefit to NP-guided therapy in broader populations.

Clinical Algorithm for ProBNP Use

Use ProBNP/NT-proBNP for:

1. Initial diagnosis when HF is suspected (high sensitivity 86-96%, rules out HF effectively) 4
2. Baseline risk assessment at admission
3. Predischarge prognostication to identify high-risk patients needing closer follow-up 1
4. Screening in at-risk populations to prevent HF development (Class 2a) 1

Do NOT routinely use for:

1. Treatment titration targets in established HF
2. Serial monitoring to guide medication adjustments as primary strategy
3. Discharge timing decisions based solely on achieving specific values

Important Caveats

Obesity significantly reduces diagnostic sensitivity - BNP and NT-proBNP levels are lower in obese patients, potentially missing the diagnosis 1. Adjust clinical suspicion accordingly.

Age, sex, and renal function affect interpretation 2:

• Higher baseline values in elderly patients
• Women have higher values than men
• Renal dysfunction elevates NT-proBNP more than BNP

Atrial fibrillation elevates levels independent of HF severity 2.

The Exception: Younger Patients with HFrEF

Some evidence suggests NP-guided therapy may benefit patients with HFrEF aged <75 years 3. The STARS-BNP, PROTECT, BATTLESCARRED, and TIME-CHF studies showed reduced cardiac events and mortality in this specific subgroup. However, this remains insufficient for broad guideline endorsement.

Practical Clinical Approach

Base treatment decisions on:

• Clinical symptoms and functional status
• Physical examination findings
• Guideline-directed medical therapy optimization regardless of biomarker levels
• Echocardiographic parameters

Use ProBNP/NT-proBNP to:

• Confirm diagnosis when uncertain
• Identify patients at highest risk who need intensive follow-up
• Provide prognostic information to patients and families
• Document disease severity for care coordination

The key message: ProBNP is an excellent diagnostic and prognostic tool, but not a therapeutic target for routine management adjustments 1.